SIL-8301

· Biossil Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SIL-8301, covering 2025-12-15 to 2025-12-15. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype [Phase 2]